Does the drug Tolvaptan have any effect on decreasing the total kidney volume in patients with autosomal dominant polycystic kidney disease

Effect of Tolvaptan on total kidney volume in patients with autosomal dominant polycystic kidney disease - a 6 month follow up study.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/11/022099

Enrollment

Registered

2019-11-21

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: Q612- Polycystic kidney, adult type

Interventions

Intervention1: Tolvaptan: Split-dose regimen of oral tolvaptan (8 a.m./4 p.m.) will be started for cases at dose of 30mg and 15 mg and up-titrated every fortnight ( 45/15, 60/30, 90/30 mg/d) until tol

Eligibility

Inclusion criteria

Inclusion criteria: eGFR >25ml/min/1.73m2 Total kidney volume >750 ml

Exclusion criteria

Exclusion criteria: eGFR Total kidney volume Atypical cases of polycystic kidney disease Hepatic diseases (other than hepatic cysts) Heart failure Subjects unable to take plenty of fluids Pregnant and lactating patients Patient requiring intervention or surgery. Patients not tolerating tolvaptan. Need for diuretic use Patients with advanced diabetes mellitus

Design outcomes

Primary

Measure	Time frame
Percentage change in total kidney volume at the end of 6 monthsTimepoint: Before initiating treatment and at the end of 6 months	—

Secondary

Measure	Time frame
Percentage change in eGFR at the end of 6 monthsTimepoint: Before initiating treatment and at the end of 6 months	—

Countries

India

Contacts

Public ContactDrAnjana Asokan

Government Medical College,Kozhikode

nephcal@gmail.com9446338109

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026